학술논문
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Document Type
Article
Author
Danese, Silvio; Panaccione, Remo; Feagan, Brian G; Afzali, Anita; Rubin, David T; Sands, Bruce E; Reinisch, Walter; Panés, Julián; Sahoo, Aparna; Terry, Natalie A; Chan, Daphne; Han, Chenglong; Frustaci, Mary Ellen; Yang, Zijiang; Sandborn, William J; Hisamatsu, Tadakazu; Andrews, Jane M; D'Haens, Geert R; Oliinyk, Oleksandr; Bilianskyi, Leonid; Gniady-Jastrzebska, Jadwiga; Petryka, Robert; Arlukowicz, Tomasz; Gietka, Piotr; Zmudzinski, Marcin; Mumtaz, Syed; Wolf, Douglas; Wojcik, Katarzyna; Duvall, George; Augustyn, Monika; Filip, Rafal; Tarabar, Dino; Tkachev, Alexander; Seidler, Ursula; Zittan, Eran; Pokrotnieks, Juris; Shchukina, Oksana; Machavariani, Andro; Loy, Laura; Abu-farsakh, Niazy; Marina, Pesegova; Sreckovic, Slobodan; Laclav, Martin; Wei, Shu-Chen; Suiter, Daniel; Borsuk, Aleksey; Hebuterne, Xavier; Buning, Carsten; Lahat-Zok, Adi; Danilkiewicz, Wit; Frysna, Bernadetta; Jovicic, Ivana; Datsenko, Olena; Guram, Maninder; Jain, Animesh; Rashid, Zahid; Heeren, Sonja; Shulga, Natallia; Timkin, Ivan; Gornjakovic, Srdjan; Lukas, Milan; Altwegg, Romain; Desjeux, Ariadne; Reimund, Jean-Marie; Giorgadze, Manana; Jochum, Christoph; Ito, Hiroaki; Nakai, Katsuhiko; Takagi, Tomohisa; Zaha, Osamu; Choi, Changhwan; Kim, Taeoh; Lee, Jonghun; Stundiene, Ieva; Hilmi, Ida Normiha; Hj Md Said, Rosaida; Leszczyszyn, Jaroslaw; Abdulganieva, Diana; Fominykh, Yulia; Maksyashina, Svetlana; Balaz, Jozef; Van Domselaar, Manuel; Kav, Taylan; Dennis, Patrick; Henry, Patricia; Holmes, Robert; Johnson, Christopher; McBride, Matthew; Sarles, Harry; Moore, Gregory; Yakubtsevich, Ruslan; Muls, Vinciane; Trbojevic, Stevan; Afif, Waqqas; Bernstein, Charles; Klarin, Ivo; Serclova, Zuzana; Volfova, Miroslava; Desreumaux, Pierre; Gilletta de Saint Joseph, Cyrielle; Roblin, Xavier; Vuitton, Lucine; Chelidze, Kakhaber; Kuehbacher, Tanja; Koutroubakis, Ioannis; Cicala, Michele; Fries, Walter; Gasbarrini, Antonio; Aoyama, Nobuo; Hayashi, Yoshito; Hirai, Fumihito; Horiki, Norkiyuki; Hoshi, Namiko; Inaba, Tomoki; Hiroyasu, Ishida; Maemoto, Atsuo; Matsumoto, Takayuki; Matsushima, Kayoko; Motoya, Satoshi; Taruishi, Masaki; Rashid, Mohammed; Chun, Jaeyoung; Kim, Young-Ho; Park, Dong Il; Sharara, Ala; Jonaitis, Laimas; Deriban, Gjorgi; Brooker, James; Gawdis-Wojnarska, Beata; Wozniak-Stolarska, Barbara; Andreev, Pavel; Simanenkov, Vladimir; Trofimov, Vasiliy; Jovanovic, Igor; Zdravkovic, Natasa; Aldeguer i Mante, Xavier; Hernandez Ramirez, Vicent; Akpinar, Hale; Celebi, Gurkan; Hamzaoglu, Hulya; Fernandez, Juan; Kamath, Jayaprakash; Palekar, Nicole; Pruthi, Jatinder S.; Rausher, David; Ritter, Timothy
Source
The Lancet Gastroenterology & Hepatology; February 2024, Vol. 9 Issue: 2 p133-146, 14p
Subject
Language
ISSN
24681253
Abstract
Many patients with moderately to severely active Crohn's disease do not respond to available therapies or lose response over time. The GALAXI-1 study previously found that three intravenous guselkumab dosages showed superior clinical and endoscopic outcomes over placebo at week 12 in patients with moderately to severely active Crohn's disease. We report the safety and efficacy of subcutaneous guselkumab maintenance regimens to week 48 in the GALAXI-1 study.